Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats

Drug Delivery

Volumn 22, Issue 1, 2015, Pages 86-93

  Li, Xingang ^a,b   Zhao, Zhigang ^b   Li, Liang ^a   Zhou, Tianyan ^a,c   Lu, Wei ^a,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Exenatide; in vitro and in vivo correlation; Microspheres; Pharmacokinetics; Transit compartment model

Indexed keywords

EXENDIN 4; GLUCOSE; MICROSPHERE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PEPTIDE; SOLVENT; STREPTOZOCIN; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SOLUBILITY; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SUSPENSION; SUSTAINED DRUG RELEASE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MEDICINAL CHEMISTRY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MICROSPHERES; MODELS, BIOLOGICAL; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SOLVENTS; STREPTOZOCIN; VENOMS;

EID: 84920280647     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.871760     Document Type: Article

References (31)

1. Balan G, Timmins P, Greene DS, et al. (2001). In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. J Pharm Sci 90:1176-85.
2. Buchwald P. (2003). Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method. J Pharm Pharmacol 55:495-504.
3. Burgess DJ, Hussain AS, Ingallinera TS, et al. (2002). Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci 4:E7-8.
4. Eng J, Kleinman WA, Singh L, et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-5.
5. Goke R, Fehmann HC, Linn T, et al. (1993). Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1 - (7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-5.
6. Hamberg AK, Dahl ML, Barban M, et al. (2007). A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 81:529-38.
7. Haruta S, Kawai K, Nishii R, et al. (2002). Prediction of plasma concentration-time curve of orally administered theophylline based on a scintigraphic monitoring of gastrointestinal transit in human volunteers. Int J Pharm 233:179-90.
8. Jantratid E, De Maio V, Ronda E, et al. (2009). Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci 37:434-41.
9. Jiang G, Qiu W, DeLuca PP. (2003). Preparation and in vitro/in vivo evaluation of insulin-loaded poly (acryloyl-hydroxyethyl starch) - PLGA composite microspheres. Pharm Res 20:452-9.
10. Jiang G, Woo BH, Kang FR, et al. (2002). Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly (D, L-lactide-co-glycolide) microspheres. J Control Release 79:137-45.
11. Kagan L, Hoffman A. (2008). Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur J Pharm Biopharm 69:238-46.
12. Kwak HH, Shim WS, Hwang S, et al. (2009). Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm Res 26:2504-12.
13. Lehto P, Kortejarvi H, Liimatainen A, et al. (2011). Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs. Eur J Pharm Biopharm 78:531-8.
14. Li L, Li ZQ, Deng CH, et al. (2012a). A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. Acta Pharmacol Sin 33:127-36.
15. Li XG, Li L, Wang XP, et al. (2012b). Application of model-based methods to characterize exenatide-loaded double-walled microspheres: In vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation. J Pharm Sci 101:3946-61.
16. Li XG, Li L, Zhou X, et al. (2012c). Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. Acta Pharm Sin 33:1379-86.
17. Machida Y, Onishi H, Kurita A, et al. (2000). Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J Control Release 66:159-75.
18. Parkes DG, Jodka C, Smith P, et al. (2001). Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Develop Res 53:260-7.
19. Parkes DG, Nielsen LL, Young AA. (2004). Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117:77-88.
20. Reed MJ, Meszaros K, Entes LJ, et al. (2000). A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49:1390-4.
21. Sah H. (1997). A new strategy to determine the actual protein content of poly (lactide-co-glycolide) microspheres. J Pharm Sci 86:1315-18.
22. Savic RM, Jonker DM, Kerbusch T, et al. (2007). Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-26.
23. Soriano I, Evora C, Llabres M. (1996). Preparation and evaluation of insulin-loaded poly (DL-lactide) microspheres using an experimental design. Int J Pharm 142:135-42.
24. Spenlehauer G, Vert M, Benoit JP, et al. (1989). In vitro and in vivo degradation of poly (D, L lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials 10:557-63.
25. Sun Y, Wang J, Zhang X, et al. (2008). Synchronic release of two hormonal contraceptives for about one month from the PLGA microspheres: in vitro and in vivo studies. J Control Release 129:192-9.
26. Sun YN, Jusko WJ. (1998). Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732-7.
27. Tracy MA, Ward KL, Firouzabadian L, et al. (1999). Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20:1057-62.
28. Ye ML, Kim S, Park K. (2010). Issues in long-term protein delivery using biodegradable microparticles. J Control Release 146:241-60.
29. Young AA, Gedulin BR, Bhavsar S, et al. (1999). Glucose-lowering and insulin-sensitizing actions of exendin-4 Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-34.
30. Yu LX, Lipka E, Crison JR, et al. (1996). Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 19:359-76.
31. Zolnik BS, Burgess DJ. (2008). Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 127:137-45.